Vijaya Diagnostic Centre IPO to open on Sept 1 at fixed price band of Rs522-531 per equity share
Vijaya Diagnostic Centre IPO to open on Sept 1 at fixed price band of Rs522-531 per equity share
The Floor Price is 522 times the face value of the Equity Shares and the Cap Price is 531 times the face value of the Equity Shares.
Vijaya Diagnostic Centre Limited proposes to open its Initial Public Offering on Wednesday, September 01, 2021. The Offer will close on Friday, September 03, 2021.
The Price Band of the offer has been fixed at Rs522 to Rs531 per Equity Share. Bids can be made for a minimum of 28 Equity Shares and in multiple of 28 Equity Shares thereafter.
The Initial Public Offering comprises of an offer for sale of up to 35,688,064 Equity Shares by the Selling Shareholders, comprising of up to 5,098,296 Equity Shares by Dr. S. Surendranath Reddy (“Promoter Selling Shareholder”), up to 29,487,290 Equity Shares by Karakoram Limited and up to 1,102,478 Equity Shares by Kedaara Capital Alternative Investment Fund- Kedaara Capital AIF 1 (“Karakoram Limited together with Kedaara Capital Alternative Investment Fund –Kedaara Capital AIF 1 referred to as “Investor Selling Shareholders”).
The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that our Company and the Selling Shareholders in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price. 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs.
Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to RIBs in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank account (including UPI ID for RIBs using UPI Mechanism), in which the corresponding Bid Amounts will be blocked by the SCSBs or the Sponsor Bank, as applicable. Anchor Investors are not permitted to participate in the Offer through the ASBA process
The object of the offer are to (i) to carry out the Offer for Sale of up to 35,688,064 Equity Shares by the Selling Shareholders; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges. Company will not receive any proceeds from the Offer and all such proceeds (net of any Offer related expenses to be borne by the Selling Shareholders) will go to the Selling Shareholders.
The company expects that listing of the Equity Shares will enhance its visibility and brand image and provide liquidity to Shareholders and will also provide a public market for the Equity Shares in India.
ICICI Securities Limited, Edelweiss Financial Services Limited and Kotak Mahindra Capital Company Limited are the Book Running Lead Managers to the issue.
The Equity Shares to be offered through the Red Herring Prospectus are proposed to be listed on BSE and NSE.
The Company derives 64.98% of total revenue from sale of products from India and 35.02% of total revenue from the sale of products from Europe, the USA and other foreign countries combined. Below are the 10 things to know about the Sansera Engineering
Bid can be made for a minimum of 24 Equity Shares and in multiples of 24 Equity Shares thereafter. Ami Organics Limited has allocated 28,01,485 equity shares to 20 anchor investors and raised Rs170.89cr ahead of the company’s proposed IPO at the upper
The price band for the public issue has been fixed at Rs522-531. Vijaya Diagnostic has finalized 29 anchor investors, allotting 10,661,418 shares at Rs531 per share aggregating Rs566.12cr. The list includes high-quality long-only investors such as Fidelity
As per the F&S Report, the company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban. Here is a top thing to know about AMI Organics Limited IPO: 1.
The issue will have a price band of Rs522 to Rs531 per equity share of the face value of Re. 1 each (“Equity Shares”). Here is a top thing to know about Vijaya Diagnostic Center Limited IPO: 1) The Issue: The Initial Public Offering comprises of an offer